The Geriatric Emergency Department Pharmacologic Harm Prevention Project
This study is looking at whether using your DNA information (pharmacogenomic testing) can help doctors choose medications more safely for older adults who take five or more medicines. The goal is to reduce side effects, especially falls, and improve overall medication safety. You might be eligible if you are 65 to 110 years old and recently had a fall. Researchers will compare two groups: one where doctors get your DNA results to guide prescribing, and another where doctors provide usual care. The study will measure how many times people fall, how many emergency room visits are due to medication side effects, and overall mortality after 6-7 months. The study plans to enroll 1000 participants, but its current status is unclear.
- Study design
- This interventional study plans to enroll 1000 participants aged 65-110 years. It compares two groups: one receiving DNA-guided care and another receiving usual care.
- What's involved
- You would have follow-up assessments by telephone approximately 14 days after enrollment and then monthly for six months.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for 6-7 months to assess recurrent falls, emergency department visits, and all-cause mortality.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
At a glance
Conditions
NCT07216846
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Delray Medical Center
Delray Beach, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Richard Shih, MD · PRINCIPAL_INVESTIGATOR · Florida Atlantic University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Recurrent falls -self reported and chart review6-7 months
Incidence of recurrent falls during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any falls that may have occurred. In addition, each participant will receive a calendar to record falls during the month. At six-month, the primary care physician medical records will be reviewed to check for any additional falls.
- Incidence of ADE-related ED visits- self reported and chart reviewTime Frame: 6-7 months
Incidence of ADE-related ED visits during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any ADE-related ED visits that may have occurred. At six-month, the primary care physician medical records will be reviewed to check for any additional ADE-related ED visits.
- All-cause mortality - Florida Death RegistryTime Frame: 6-7 months
During 6-7 months of follow-up. All participants will be cross-referenced with the Florida Death Registry to identify mortality outcomes